Dyadic International Investor Relations Material
Latest events
Q1 2025
Dyadic International
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dyadic International Inc
Access all reports
Dyadic International Inc. is a biotechnology company specializing in the development and commercialization of technologies for gene expression and protein production. The company’s primary platform, the C1 gene expression system, is used to produce enzymes and proteins for various industries, including biopharmaceuticals, vaccines, and industrial applications. Dyadic focuses on leveraging its proprietary technology to accelerate the development of biologics and other biotechnological products, aiming to improve production efficiency and scalability. The company is headquartered in Jupiter, Florida, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
DYAI
Country
🇺🇸 United States